Deutsche Bank AG Buys 91,359 Shares of 908 Devices Inc. (NASDAQ:MASS)

Deutsche Bank AG increased its stake in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) by 1,159.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 99,239 shares of the company's stock after buying an additional 91,359 shares during the quarter. Deutsche Bank AG owned 0.29% of 908 Devices worth $218,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. D. E. Shaw & Co. Inc. grew its stake in 908 Devices by 49.1% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 85,860 shares of the company's stock valued at $189,000 after purchasing an additional 28,263 shares during the period. Bank of America Corp DE grew its stake in 908 Devices by 190.9% in the 4th quarter. Bank of America Corp DE now owns 94,753 shares of the company's stock valued at $208,000 after purchasing an additional 62,179 shares during the period. Jane Street Group LLC grew its stake in 908 Devices by 118.9% in the 4th quarter. Jane Street Group LLC now owns 113,890 shares of the company's stock valued at $251,000 after purchasing an additional 61,851 shares during the period. Northern Trust Corp grew its stake in 908 Devices by 7.5% in the 4th quarter. Northern Trust Corp now owns 200,764 shares of the company's stock valued at $442,000 after purchasing an additional 14,087 shares during the period. Finally, Hsbc Holdings PLC grew its stake in 908 Devices by 32.2% in the 4th quarter. Hsbc Holdings PLC now owns 21,007 shares of the company's stock valued at $46,000 after purchasing an additional 5,112 shares during the period. Institutional investors own 88.06% of the company's stock.

908 Devices Price Performance

Shares of NASDAQ:MASS traded up $0.28 on Wednesday, hitting $6.90. The company's stock had a trading volume of 742,710 shares, compared to its average volume of 1,006,994. The company has a 50-day simple moving average of $4.87 and a 200 day simple moving average of $3.45. 908 Devices Inc. has a 1 year low of $1.81 and a 1 year high of $7.30. The company has a market capitalization of $247.44 million, a PE ratio of -3.90 and a beta of 0.29.

908 Devices (NASDAQ:MASS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.05. The company had revenue of $11.78 million for the quarter, compared to analysts' expectations of $11.90 million. 908 Devices had a negative return on equity of 24.60% and a negative net margin of 109.11%. On average, equities research analysts expect that 908 Devices Inc. will post -1.99 earnings per share for the current fiscal year.

Insider Activity at 908 Devices

In other news, Director Mark Spoto acquired 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The shares were bought at an average cost of $4.29 per share, with a total value of $42,900.00. Following the acquisition, the director now owns 62,971 shares in the company, valued at approximately $270,145.59. This represents a 18.88% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 23.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of 908 Devices in a research report on Saturday, May 24th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $5.33.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.